251 results match your criteria Clinical Medicine Insights: Oncology [Journal]


Myoepithelial Cell Carcinoma of the Oral Tongue: Case Report and Review of the Literature.

Clin Med Insights Oncol 2019 2;13:1179554919838254. Epub 2019 Apr 2.

Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of New Mexico Hospital, UNM School of Medicine, Albuquerque, NM, USA.

Background: Myoepithelial cell carcinoma is a rare malignant neoplasm of salivary gland origin that typically presents in the parotid gland and minor salivary glands. It has been described previously in head and neck sites such as buccal mucosa, alveolar ridge, and base of tongue.

Methods: A 55-year-old man presented with 30 years of right-sided tongue pain and 10 years of gradually worsening ulceration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554919838254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448097PMC
April 2019
2 Reads

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer.

Clin Med Insights Oncol 2019 7;13:1179554919833927. Epub 2019 Mar 7.

Genitourinary (GU) Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA.

Non-metastatic castration-resistant prostate cancer (nmCRPC) is a heterogeneous disease with variable potential in developing into overt metastases. It is an area of increased unmet need in advanced prostate cancer and for which there had been no great treatments until recent US Food and Drug Administration (FDA) approval of 2 novel anti-androgens apalutamide and enzalutamide, which were both approved given benefit in metastasis-free survival. Early data on the use of darolutamide, another novel anti-androgen, are also explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554919833927DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407161PMC

PAK1 Expression in Pancreatic Cancer: Clinicopathological Characteristics and Prognostic Significance.

Clin Med Insights Oncol 2019 18;13:1179554919831990. Epub 2019 Feb 18.

2nd Department of Surgery and Laboratory of Experimental Surgery-Postgraduate Program in Hepatobiliary/Pancreatic Surgery, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

Background: Improvement of the management of pancreatic cancer requires a better understanding of the genetic and molecular changes responsible for the development of the disease. The family of p21-activated kinases (PAKs) and especially PAK1 appears to mediate many cellular processes that contribute to the development and progression of pancreatic cancer, but the clinical relevance of PAK1 expression with the disease still remains unclear. Aim of the study was to assess the clinical value and the potential prognostic significance of PAK1 in pancreatic adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554919831990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379789PMC
February 2019
1 Read

Access to Palliative Care for Cancer Patients Living in a Northern and Rural Environment in Ontario, Canada: The Effects of Geographic Region and Rurality on End-of-Life Care in a Population-Based Decedent Cancer Cohort.

Clin Med Insights Oncol 2019 14;13:1179554919829500. Epub 2019 Feb 14.

Northeast Cancer Centre, Health Sciences North Research Institute, Sudbury, ON, Canada.

Background: Access to palliative care has been associated with improving quality of life and reducing the use of potentially aggressive end-of-life care. However, many challenges and barriers exist in providing palliative care to residents in northern and rural settings in Ontario, Canada.

Aim: The purpose of this study was to examine access to palliative care and associations with the use of end-of-life care in a decedent cohort of northern and southern, rural and urban, residents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554919829500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378418PMC
February 2019
1 Read

A Surgical Case of Inflammatory Myofibroblastic Tumor of the Liver: Potentially Characteristic Gross Features.

Clin Med Insights Oncol 2019 12;13:1179554919829498. Epub 2019 Feb 12.

Department of Surgery, National Hospital Organization, Fukuyama Medical Center, Fukuyama, Japan.

We herein reported a very rare surgical case of inflammatory myofibroblastic tumor (IMT) of the liver, showing potentially unique and specific gross findings on its cut surface: our IMT demonstrated a relatively well-demarcated and partly infiltrative and likely extrahepatic (ie serosal) but not intrahepatic mass, appearing firm and hemorrhagic, and yellow-whitish in color. The patient, who was a woman in her early 70s with 2-year follow-up for lung cryptococcosis and traffic accident, incidentally presented with unenhanced and low-density, heterogeneous mass on abdominal dynamic CT in the peripheral right lobe of the liver. We could conclusively diagnose the current lesion as the hepatic IMT after thorough analyses including a wide panel of immunohistochemical antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554919829498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378515PMC
February 2019
1 Read

Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune System.

Clin Med Insights Oncol 2019 29;13:1179554918825449. Epub 2019 Jan 29.

Novocure Ltd., Haifa, Israel.

Background: Tumor treating fields (TTFields) are a non-invasive antimitotic therapy that delivers alternating electric fields via the Optune system. The Phase III EF-14 trial in newly diagnosed glioblastoma multiforme (GBM) showed significantly improved progression-free, overall and long-term survival when Optune was used together with maintenance temozolomide (TMZ) compared with TMZ alone. Compliance (average monthly use) was associated with better clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918825449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351720PMC
January 2019

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study.

Clin Med Insights Oncol 2019 30;13:1179554918825447. Epub 2019 Jan 30.

Medical Oncology Section, The Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Background: Regorafenib is a multi-kinase inhibitor approved for treatment of refractory advanced colorectal cancer. It was found in the clinical trials to have a modest benefit and significant toxicity. Our aim was to assess the outcome in our local clinic practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918825447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354297PMC
January 2019
4 Reads

Hepatotoxicities Induced by Neoadjuvant Chemotherapy in Colorectal Cancer Liver Metastases: Distinguishing the True From the False.

Clin Med Insights Oncol 2019 22;13:1179554918825450. Epub 2019 Jan 22.

Digestive Tumours Unit, Institut Bergonié, Bordeaux, France.

Background: Pre-operative chemotherapy for colorectal liver metastasis (CRLM) is thought to be the cause of hepatotoxicity of non-tumoural parenchyma. Studies on hepatotoxicity are contradictory. We investigated the impact of a single-line pre-operative chemotherapy on non-tumoural liver analysed by an expert hepatico-pancreatico-biliary pathologist, and the consequences on surgical outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918825450DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348554PMC
January 2019
2 Reads

The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy.

Clin Med Insights Oncol 2019 7;13:1179554918821320. Epub 2019 Jan 7.

Department of Clinical Physiology and Nuclear Medicine, Herlev Hospital, Herlev, Denmark.

Introduction: Cisplatin is used as treatment for several different malignancies and a well-known complication is irreversible kidney damage. To protect the kidneys, this treatment is often combined with mannitol infusion to promote osmotic diuresis. Earlier studies investigating the nephroprotective effect of mannitol have shown conflicting results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918821320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327333PMC
January 2019
2 Reads

Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience.

Clin Med Insights Oncol 2019 9;13:1179554918821314. Epub 2019 Jan 9.

Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.

Background: In recent years, the anti-programmed cell death 1 (PD-1) drug pembrolizumab (Keytruda) was approved for treatment of unresectable advanced non-small cell lung cancer (NSCLC) as first- or second-line therapy depending on the clone 22C3-programmed death-ligand 1 (PD-L1) immunohistochemical expression score by the companion diagnostic assay. We herein evaluated 22C3-PD-L1 expression of NSCLC in a single institution experience and compared it with clinicopathologic features.

Materials And Methods: We assessed 22C3-PD-L1 expressions of 411 patients with NSCLC from our institution, including in past specimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918821314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329032PMC
January 2019
3 Reads

Correlation Between the Sites of Onset of Basal Cell Carcinoma and the Embryonic Fusion Planes in the Auricle.

Clin Med Insights Oncol 2018 7;12:1179554918817328. Epub 2018 Dec 7.

Advanced Technologies for Regenerative Medicine and Inductive Surgery Research Center, University of Pavia, Pavia, Italy.

Objectives: This study aims at the identification of the distribution of basal cell carcinomas (BCCs) in the auricle in correlation with the currently most credited sites of the embryonic fusion planes of the auricle.

Methods: An overall number of 69 patients with 72 BCCs of the auricle were enrolled in the study over a period of 14 years, from June 2003 to October 2017. All the cases underwent medical preoperative digital photography and the specific location of each BCC was coded on an original full-size anatomical diagram of the auricle derived from the reports by Streeter, Wood-Jones, Park, Porter, and Minoux showing the currently most credited sites of the embryonic fusion planes arbitrarily featured as two 5-mm-wide ribbon-like areas: (1) the hyoid-mandibular fusion plane (HM-FP) running from the upper margin of the tragus toward the concha and then deflecting toward the lower margin of the tragus and (2) the free ear fold-hyoid fusion plane (FEFH-FP) running from the cranial-most portion of the helix to the mid-portion of the ascending helix. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918817328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293364PMC
December 2018
9 Reads

Consensus on molecular imaging and theranostics in prostate cancer.

Lancet Oncol 2018 Dec;19(12):e696-e708

Department of Nuclear Medicine, Radboud University Medical Centre, Nijmegen, Netherlands; Department of Nuclear Medicine, The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, London, UK.

Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183060
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30604-1DOI Listing
December 2018
27 Reads

A Rare Primary Tumor of the Thyroid Gland: A New Case of Leiomyoma and Literature Review.

Clin Med Insights Oncol 2018 26;12:1179554918813535. Epub 2018 Nov 26.

Department of Pathology, Wanbei Coal-Electricity Group General Hospital, Suzhou, China.

Primary leiomyomas of the thyroid are very rare. We here report a case of a 53-year-old woman with a painless mass at the right thyroid, revealed by physical examination. The patient underwent a lobectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918813535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256313PMC
November 2018
3 Reads

Corrigendum.

Authors:

Clin Med Insights Oncol 2018 25;12:1179554918803688. Epub 2018 Sep 25.

[This corrects the article DOI: 10.1177/1179554918782477.]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918803688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158601PMC
September 2018
1 Read

A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown Mutation Status.

Clin Med Insights Oncol 2018 21;12:1179554918794672. Epub 2018 Aug 21.

Department of General Surgery, Mackay Memorial Hospital, Taipei, Taiwan.

The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and overall survival (OS) of patients with resected stage I-III TNBC who were treated with or without cisplatin-containing chemotherapy (CisCT or noCisCT) during 2004 and 2010. Of 129 patients, 25 received CisCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918794672DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104219PMC
August 2018
11 Reads

Early Clinical Outcomes, Patterns of Failure, and Acute Haematologic Toxicity of Image-Guided Volumetric Modulated Arc Therapy (IG-VMAT) in the Definitive Treatment of Locally Advanced Carcinoma Cervix.

Clin Med Insights Oncol 2018 27;12:1179554918783990. Epub 2018 Jun 27.

Department of Radiotherapy, Batra Hospital & Medical Research Centre, New Delhi, India.

Purpose: To evaluate clinical outcomes and failure patterns in patients with locally advanced cervical cancer (LACC) treated definitively using image-guided volumetric-modulated arc therapy (IG-VMAT).

Methods And Materials: This retrospective review included 18 consecutively treated patients with LACC. Treatment consisted of IG-VMAT and concurrent chemotherapy followed by intracavitary radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918783990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081749PMC
June 2018
3 Reads

Survival Study of Triple-Negative and Non-Triple-Negative Breast Cancer in a Brazilian Cohort.

Clin Med Insights Oncol 2018 27;12:1179554918790563. Epub 2018 Jul 27.

Post-Graduate Program in Health, Faculty of Medicine, Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Brazil.

Objective: To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Brazilian cohort and identify potential prognostic factors.

Methods: This hospital-based retrospective cohort study included 447 women with breast cancer treated at referral centers in Southeastern Brazil. Overall and disease-free survival were compared; prognostic factors were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918790563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071162PMC
July 2018
2 Reads

Identifying Risk Factors for Morbidity and Mortality in Patients with Primary Head and Neck Cancers in a Nigerian Population.

Clin Med Insights Oncol 2018 25;12:1179554918783986. Epub 2018 Jun 25.

Department of Otorhinolaryngology, Head and Neck Surgery, Jos University Teaching Hospital, Jos, Nigeria.

Background: The risk factors for head and neck cancers (HNC) vary in different parts of the world.

Objectives: To identify the risk factors for HNC and the correlation between these factors and the involved anatomical sites.

Methods: We retrieved and analyzed health records of patients that met the inclusion criteria for HNC managed at our facility in a 10-year period using the International Classification of Diseases (ICD) version 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918783986DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055237PMC
June 2018
6 Reads

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience.

Clin Med Insights Oncol 2018 28;12:1179554918782475. Epub 2018 Jun 28.

Department of Medical Oncology, HCG Cancer Speciality Center, Bangalore, India.

Background: Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated patients with MBC.

Methods: In this study, a total of 45 eligible patients with MBC who received eribulin in HCG Cancer Speciality Center from November 2014 to March 2016 were prospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918782475DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055235PMC
June 2018
26 Reads

A Single-Centre Experience on the Management of Adenosarcoma: A Successful Report of an Integrated Medical and Surgical Approach.

Clin Med Insights Oncol 2018 18;12:1179554918782477. Epub 2018 Jun 18.

Department of Specialized, Experimental and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

Adenosarcomas are the rarest form of uterine sarcomas, and clinical experience with their management is still limited. Here, we reported 7 patients with uterine adenosarcoma referred to our institution, focusing on main pathologic features, their medical history, and long-term follow-up. Among these patients, we provided a detailed description of the medical history of a 49-year-old woman with advanced uterine adenosarcoma with sarcomatous overgrowth who presented a brilliant radiologic and pathologic response after 3 cycles of epirubicin and ifosfamide, ultimately achieving an extraordinary long-term outcome through an integrated surgical and medical approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918782477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024524PMC
June 2018
24 Reads

Malignant Peritoneal Mesothelioma in the setting of a Ventriculo-Peritoneal Shunt: A novel clinical presentation.

Clin Med Insights Oncol 2018 5;12:1179554918779583. Epub 2018 Jun 5.

Department of Pathology, University of South Alabama, Mobile, AL, USA.

We report a case of malignant peritoneal mesothelioma (MPM) in a 31-year-old male with history of cerebral palsy, hydrocephalus, and ventriculoperitoneal shunt (VPS) placed since infancy. He presented with fever, abdominal pain and distension. Computed tomography scan revealed a thick-walled rim-enhancing fluid collection, interpreted as pseudocyst. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918779583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992800PMC
June 2018
7 Reads

Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review.

Clin Med Insights Oncol 2018 4;12:1179554918779587. Epub 2018 Jun 4.

Division of Hematology & Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.

Objective: Bevacizumab is approved for use in combination with chemotherapy for metastatic/recurrent cervical cancer (CC), with increased survival/response rates. However, use of bevacizumab is not always feasible or safe. The purpose of this study was to identify the percentage of metastatic/recurrent CC patients at our institution who would have been eligible to receive bevacizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918779587DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989046PMC
June 2018
2 Reads

The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor-Mutated Stage IIIB or IV Non-Small-Cell Lung Cancer Patients.

Clin Med Insights Oncol 2018 4;12:1179554918779585. Epub 2018 Jun 4.

Gundersen Lutheran Medical Center, Gundersen Health System, La Crosse, WI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918779585DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989053PMC
June 2018
2 Reads

Precision Medicine in Head and Neck Cancer: Myth or Reality?

Clin Med Insights Oncol 2018 4;12:1179554918779581. Epub 2018 Jun 4.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada.

Standard treatment in head and neck squamous cell carcinoma (HNSCC) is limited currently with decisions being made primarily based on tumor location, histology, and stage. The role of the human papillomavirus in risk stratification is actively under clinical trial evaluations. The molecular complexity and intratumoral heterogeneity of the disease are not actively integrated into management decisions of HNSCC, despite a growing body of knowledge in these areas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918779581DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989049PMC
June 2018
3 Reads

Methylation and Gene Expression of and in Colorectal Cancer Tissues.

Clin Med Insights Oncol 2018 10;12:1179554918775064. Epub 2018 May 10.

Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, SA, Australia.

The genes and are hypermethylated in colorectal cancer (CRC), but little is known about how this relates to gene expression. This study assessed the relationship between methylation and gene expression of and in CRC and adjacent non-neoplastic tissues. The tissues were obtained at surgery from 36 patients diagnosed with different stages of CRC (stage I n = 8, stage II n = 13, stage III n = 10, stage IV n = 5). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918775064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952276PMC
May 2018
3 Reads

Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature.

Clin Med Insights Oncol 2018 9;12:1179554918763367. Epub 2018 Apr 9.

Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.

Metastatic pheochromocytoma and paraganglioma (mPHEO/PGL) are frequently associated with () mutations. Cyclophosphamide-dacarbazine-vincristine (CVD) regimen is recommended as standard chemotherapy for advanced mPHEO/PGL. There is limited evidence to support the role of metronomic schemes (MS) of chemotherapy in mPHEO/PGL treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918763367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922490PMC
April 2018
14 Reads

Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.

Curr Treat Options Oncol 2018 04 16;19(5):23. Epub 2018 Apr 16.

Lester and Sue Smith Breast Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA.

Opinion Statement: Neoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular basis for intrinsic resistance to endocrine therapy and promise a more rational basis and precise approach to the systemic treatment of ER+ breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0538-9DOI Listing
April 2018
4 Reads

Eradicating Cancer Stem Cells: Concepts, Issues, and Challenges.

Curr Treat Options Oncol 2018 03 20;19(4):20. Epub 2018 Mar 20.

Laboratory of Molecular Medicine, Department of Human Genetics and Molecular Medicine, Central University of Punjab, Mansa Road, Bathinda, Punjab, 151001, India.

Opinion Statement: The cells of malignant cancers result in the evolution of cells with stem-like characteristics, commonly known as cancer stem cells (CSCs). Progress of anticancer therapies is severely hampered because of disease relapse mostly in a more aggressive form due to CSCs. These CSCs are more or less like embryonic or tissue stem cells, known for their capacity of self-renewal, exactly recapitulate of the original tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0533-1DOI Listing
March 2018
9 Reads
1 Citation

Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.

Clin Med Insights Oncol 2018 26;12:1179554918759079. Epub 2018 Feb 26.

Drug Development Unit, The Royal Marsden Hospital, London, UK.

Over the past decade, precision cancer medicine has driven major advances in the management of advanced solid tumours with the identification and targeting of putative driver aberrations transforming the clinical outcomes across multiple cancer types. Despite pivotal advances in the characterization of genomic landscape of glioblastoma, targeted agents have shown minimal efficacy in clinical trials to date, and patient survival remains poor. Immunotherapy strategies similarly have had limited success. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918759079DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833160PMC
February 2018
5 Reads

Hodgkin Lymphoma: Differences in Treatment Between Europe and the United States/North America: Evolving Trends in Protocol Therapy.

Clin Med Insights Oncol 2018 31;12:1179554918754885. Epub 2018 Jan 31.

Department of Radiation Oncology, University of Massachusetts Medical School, Worcester, MA, USA.

With continued progress and success in clinical care, the management of patients with Hodgkin lymphoma (HL) has undergone continuous revision to improve patient care outcomes and limit acute and late treatment effects on normal tissue imposed by therapy. Hodgkin lymphoma is a disease that affects children, adolescents, and adults. Clinical management strategies are influenced by the patient's age at diagnosis, tumor burden, response to induction therapy, and potential expectation of treatment impact on normal tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554918754885DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802698PMC
January 2018
6 Reads

Clinical Characteristics of Patients With Renal Cell Carcinoma and Metastasis to the Thyroid Gland.

Clin Med Insights Oncol 2017 7;11:1179554917743981. Epub 2017 Dec 7.

Wake Forest School of Medicine, Winston-Salem, NC, USA.

Introduction: Renal cell carcinoma (RCC) is the most common malignancy to metastasize to the thyroid gland. The aims of this study are as follows: (1) to analyze the clinical characteristics of patients with thyroid involvement of RCC and (2) in patients with RCC thyroid metastasis, to determine whether RCC metastasis to glandular organs only portends a better prognosis compared with other patterns of RCC metastasis.

Methods: Patients from Wake Forest Baptist Medical Center (WFBMC) diagnosed with thyroid metastasis from RCC were identified and medical records retrospectively examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917743981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724630PMC
December 2017
8 Reads

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Lancet Oncol 2017 11 31;18(11):e653-e706. Epub 2017 Oct 31.

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30698-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178838PMC
November 2017
45 Reads

Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes.

Clin Med Insights Oncol 2017 7;11:1179554917738765. Epub 2017 Nov 7.

Radiation Oncology Department, University and Spedali Civili Hospital, Brescia, Italy.

Background/aim: Low dose rate brachytherapy has been used as salvage therapy for locally recurrent prostate cancer (PC) after primary external beam radiation therapy (EBRT), along with surgery and cryotherapy. All these techniques, in particular, when applied to the whole gland, involve a relatively high risk of toxicity and may worsen the patient's quality of life. Our aim is to evaluate the results of whole-gland salvage brachytherapy (SBT) after primary EBRT in terms of toxicity, functional outcomes, and efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917738765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680931PMC
November 2017
10 Reads

Consequences of Different Corticosteroids on Serum Potassium and Prostate-Specific Antigen in Patients Receiving Abiraterone for Castration-Resistant Prostate Cancer: A Retrospective Observational Study.

Clin Med Insights Oncol 2017 30;11:1179554917737736. Epub 2017 Oct 30.

Department of Pharmacy, Juntendo University Nerima Hospital, Tokyo, Japan.

Background: Abiraterone acetate is an androgen synthesis inhibitor approved for the treatment of castration-resistant prostate cancer (CRPC). Although co-administration of either prednisone or prednisolone at 10 mg/d has been recommended to reduce the risk of abiraterone-induced hyperaldosteronism (notably hypokalemia) and to give adjunctive pain relief effects, whether these glucocorticoids can be substituted by dexamethasone remains unknown.

Methods: We performed a retrospective review of medical records of patients who were given abiraterone for the treatment of CRPC with either prednisolone (ABI/PSL) 10 mg/d or dexamethasone (ABI/DEX) 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917737736DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666518PMC
October 2017
14 Reads

Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study.

Clin Med Insights Oncol 2017 9;11:1179554917733449. Epub 2017 Oct 9.

National Institute of Demographic and Economic Analysis, The University of Waikato, Hamilton, New Zealand.

Introduction: Reduction in bone mineral density (BMD) is a common side effect of androgen deprivation therapy (ADT). We aimed to examine the cross-sectional and longitudinal variation in BMD and associated bone markers in patients with nonmetastatic prostate cancer (PCa) managed with and without ADT.

Methods: Bone mineral density of the total body, lumbar spine, femoral neck, ultradistal forearm, and one-third distal radius was measured in 88 patients with PCa without bone metastases at baseline and at 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917733449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638161PMC
October 2017
12 Reads

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

Clin Med Insights Oncol 2017 26;11:1179554917731072. Epub 2017 Sep 26.

Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA, USA.

Hodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most patients are diagnosed in their teens or twenties and are expected to live decades beyond their treatment. Therefore, the toxicity of treatment must be balanced with the goal of cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917731072DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624347PMC
September 2017
9 Reads

Factors Affecting Adjuvant Therapy in Stage III Pancreatic Cancer-Analysis of the National Cancer Database.

Clin Med Insights Oncol 2017 31;11:1179554917728040. Epub 2017 Aug 31.

Division of Hematology/Oncology, School of Medicine, Creighton University, Omaha, NE, USA.

Background: Adjuvant therapy after curative resection is associated with survival benefit in stage III pancreatic cancer. We analyzed the factors affecting the outcome of adjuvant therapy in stage III pancreatic cancer and compared overall survival with different modalities of adjuvant treatment.

Methods: This is a retrospective study of patients with stage III pancreatic cancer listed in the National Cancer Database (NCDB) who were diagnosed between 2004 and 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917728040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582659PMC
August 2017
22 Reads

Cytogenetic Profile and Gene Mutations of Childhood Acute Lymphoblastic Leukemia.

Clin Med Insights Oncol 2017 24;11:1179554917721710. Epub 2017 Jul 24.

Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Background: Childhood acute lymphoblastic leukemia (ALL) is characterized by recurrent genetic aberrations. The identification of those abnormalities is clinically important because they are considered significant risk-stratifying markers.

Aims: There are insufficient data of cytogenetic profiles in Saudi Arabian patients with childhood ALL leukemia. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1179554917721710
Publisher Site
http://dx.doi.org/10.1177/1179554917721710DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528943PMC
July 2017
33 Reads

Accuracy of [Fluorine]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography-Computed Tomography Response Assessment Following (Chemo)radiotherapy for Locally Advanced Laryngeal/Hypopharyngeal Carcinoma.

Clin Med Insights Oncol 2017 14;11:1179554917713005. Epub 2017 Jun 14.

Department of Clinical Oncology, Yorkshire Cancer Centre, Leeds, UK.

Introduction: The accuracy of response assessment positron emission tomography (PET)-computed tomography (CT) following radiotherapy with or without chemotherapy for laryngeal/hypopharyngeal squamous cell carcinoma is uncertain.

Methods: In all, 35 patients with laryngeal or hypopharyngeal squamous cell carcinoma who were treated between 2009 and 2014 with (chemo)radiotherapy were identified. The accuracy of response assessment PET-CT was made by correlation with clinical follow-up and pathological findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917713005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476423PMC
June 2017
20 Reads

V280G Mutation, Potential Role in Imatinib Resistance: First Case Report.

Clin Med Insights Oncol 2017 6;11:1179554917702870. Epub 2017 Apr 6.

Department of Hematology, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal.

Introduction: The identification of as the defining leukemogenic event in chronic myeloid leukemia (CML) and the introduction of tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction in mortality rates and accordingly an increase in the estimated prevalence of CML.

Case Report: Based on medical records and clinical follow-up, the authors present the case of a Philadelphia chromosome-positive CML patient who developed resistance to imatinib. Quantitative reverse transcription-polymerase chain reaction testing revealed a V280G mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917702870DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395261PMC
April 2017
7 Reads

Does Motion Assessment With 4-Dimensional Computed Tomographic Imaging for Non-Small Cell Lung Cancer Radiotherapy Improve Target Volume Coverage?

Clin Med Insights Oncol 2017 14;11:1179554917698461. Epub 2017 Mar 14.

Division of Radiation Oncology, Department of Radiation Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.

Introduction: Modern radiotherapy with 4-dimensional computed tomographic (4D-CT) image acquisition for non-small cell lung cancer (NSCLC) captures respiratory-mediated tumor motion to provide more accurate target delineation. This study compares conventional 3-dimensional (3D) conformal radiotherapy (3DCRT) plans generated with standard helical free-breathing CT (FBCT) with plans generated on 4D-CT contoured volumes to determine whether target volume coverage is affected.

Materials And Methods: Fifteen patients with stage I to IV NSCLC were enrolled in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917698461DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395259PMC
March 2017
8 Reads

Understanding Women's Choice of Mastectomy Versus Breast Conserving Therapy in Early-Stage Breast Cancer.

Clin Med Insights Oncol 2017 23;11:1179554917691266. Epub 2017 Feb 23.

Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, SK, Canada.

Objective: To identify factors that influence Saskatchewan women's choice between breast conserving therapy (BCT) and mastectomy in early-stage breast cancer (ESBC) and to compare and contrast underlying reasons behind choice of BCT versus mastectomy.

Methods: Interpretive description methods guided this practice-based qualitative study. Data were analyzed using thematic analysis and presented in thematic maps. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917691266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395266PMC
February 2017
29 Reads

A Study of Use of "PORT" Catheter in Patients with Cancer: A Single-Center Experience.

Clin Med Insights Oncol 2017 23;11:1179554917691031. Epub 2017 Feb 23.

Department of Medical & Pediatric Oncology, The Gujarat Cancer & Research Institute, Ahmedabad, India.

Background: Effective and reliable venous access is one of the cornerstones of modern medical therapy in oncology.

Materials And Methods: This is a prospective observational study, which collected data of patients who require "PORT" catheter insertion for any cancer, at a tertiary care oncology hospital in Ahmadabad, Gujarat, India, during a 2-year period.

Aims And Objectives: The main objective of this study was to study the various complications and outcomes related to "PORT" catheters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917691031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395272PMC
February 2017
10 Reads

Tailored Treatment of Colorectal Cancer: Surgical, Molecular, and Genetic Considerations.

Clin Med Insights Oncol 2017 16;11:1179554917690766. Epub 2017 Feb 16.

Institute of Clinical Medicine, University of Oslo, Norway.

Colorectal cancer (CRC) is a complex cancer disease, and approximately 40% of the surgically cured patients will experience cancer recurrence within 5 years. During recent years, research has shown that CRC treatment should be tailored to the individual patient due to the wide variety of risk factors, genetic factors, and surgical complexity. In this review, we provide an overview of the considerations that are needed to provide an individualized, patient-tailored treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917690766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395262PMC
February 2017
10 Reads

Effects of Serum Leptin and Resistin Levels on Cancer Cachexia in Patients With Advanced-Stage Non-Small Cell Lung Cancer.

Clin Med Insights Oncol 2017 20;11:1179554917690144. Epub 2017 Feb 20.

Medical Oncology Department, Fahri Goksin Oncology Center, Pamukkale University Hospital, Denizli, Turkey.

Introduction: Cancer cachexia is one of the most frequent effects of malignancy, is often associated with poor prognosis, and may account for up to 20% of cancer deaths. The aim of our study was to evaluate the relationship of cancer cachexia and serum levels of resistin and leptin in patients with advanced non-small cell lung cancer.

Methods: A total of 67 chemotherapy-naïve patients with advanced-stage non-small cell cancer and a control group containing 20 healthy individuals without a known chronic disease were enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554917690144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395268PMC
February 2017
11 Reads

Primary Squamous Cell Carcinoma of the Stomach.

Clin Med Insights Oncol 2017 25;11:1179554916686076. Epub 2017 Jan 25.

Department of General and Digestive Surgery, "La Paz" University Hospital, Madrid, Spain.

Squamous cell carcinoma (SCC) of the stomach is a rare entity. There are several theories regarding the development of this tumor, but its pathogenesis remains obscure. Fewer than 100 cases of primary SCC of the stomach have been published in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179554916686076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395270PMC
January 2017
14 Reads

Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunities.

Lancet Oncol 2017 01;18(1):e30-e38

Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Since the release of the Institute of Medicine report: From cancer patient to cancer survivor: lost in transition, in 2005, there has been a national call in the USA to provide coordinated, comprehensive care for cancer survivors, with an emphasis on the role of primary care. Several models of care have been described, which focus on primary care providers (PCPs) as receiving cancer survivors who are transferred after successful treatment, and who are given specific types of information from oncology-based care (eg, survivorship care plans), and not as active members of the cancer survivorship team. In this Series paper, we assessed survivorship models that have been described in the literature, with a specific focus on strategies that aim to integrate PCPs into the care of cancer survivors across different settings. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045163057
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(16)30570-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553291PMC
January 2017
9 Reads

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Lancet Oncol 2017 01 13;18(1):143-154. Epub 2016 Dec 13.

Division of Medical Oncology, Department of Medicine, Columbia University/New York Presbyterian Hospital, Manhattan, NY, USA; James J Peters VA Medical Center, Bronx, NY, USA. Electronic address:

Background: We applied mathematical models to clinical trial data available at Project Data Sphere LLC (Cary, NC, USA), a non-profit universal access data-sharing warehouse. Our aim was to assess the rates of cancer growth and regression using the comparator groups of eight randomised clinical trials that enrolled patients with metastatic castration-resistant prostate cancer.

Methods: In this retrospective analysis, we used data from eight randomised clinical trials with metastatic castration-resistant prostate cancer to estimate the growth (g) and regression (d) rates of disease burden over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30633-7DOI Listing
January 2017
38 Reads

Key Difficulties Associated with Cancer Biology.

Clin Med Insights Oncol 2016 15;10(Suppl 1):67-69. Epub 2016 Nov 15.

Doctor Specialist in Medical Oncology, Royal Bournemouth Hospital, Bournemouth, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMO.S41271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111570PMC
November 2016
9 Reads

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Clin Med Insights Oncol 2016 6;10:105-108. Epub 2016 Nov 6.

Walter Reed Military Medical Center, Bethesda, MD, USA.

As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tumor types, given a response rate of less than 10% and an overall survival of less than six months. It was broadly classified into three groups based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevitably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMO.S40429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098407PMC
November 2016
40 Reads
2 Citations